Takeda Pharmaceutical
Takeda Signs New Deal with PeptiDream Spending Billions to Develop Neuromuscular Disease Drugs
2021-07-30
Takeda to Pursue Hard-to-Drug Neurodegenerative Disease Targets with BridGene Biosciences
2021-04-01
Japan Lags Behind in COVID-19 Vaccination Goals, Looks to Hasten Approval of Second Vaccine
2021-03-15
After Five Year Oncology Alliance, Takeda Acquires Maverick to Embark on Solid Tumor Quest
2021-03-10
Neurocrine, Takeda Look to Build on Positives Post Luvadaxistat’s Schizophrenia Trial Failure
2021-03-03
Data-Driven Molecular Engineering Startup Partners with Takeda to Develop Next-Gen Gene Therapies
2021-01-26
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115